Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Don A Brigham

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Frontiers in Molecular Medicine|August 1, 2024
Phase I-II study using DeltaRex-G, a tumor-targeted retrovector encoding a cyclin G1 inhibitor for metastatic carcinoma of breastHoward W Bruckner, Sant P Chawla, Nadezhda Omelchenko, et al.
Anticancer Research|September 29, 2023
From Mendel to Gene TherapySamantha L Jeffrey, Don A Brigham, Sant P Chawla, et al.
Anticancer Research|May 29, 2023
Early-stage <i>CCNG1</i>+ HR+ HER2+ Invasive Breast Carcinoma in Older Women: Current Treatment and Future Perspectives for DeltaRex-G, a <i>CCNG1</i> InhibitorSant P Chawla, Olga Olevsky, Geeta Iyengar, et al.
Frontiers in Molecular Medicine|August 1, 2024
Three year results of Blessed: Expanded access for DeltaRex-G for an intermediate size population with advanced pancreatic cancer and sarcoma (NCT04091295) and individual patient use of DeltaRex-G for solid malignancies (IND# 19130)Sant P Chawla, Steven Wong, Doris Quon, et al.
Frontiers in Oncology|May 26, 2023
Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)Sant P Chawla, Walter Andree Tellez, Hripsime Chomoyan, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Frontiers in Molecular Medicine|August 1, 2024
Phase I-II study using DeltaRex-G, a tumor-targeted retrovector encoding a cyclin G1 inhibitor for metastatic carcinoma of breastHoward W Bruckner, Sant P Chawla, Nadezhda Omelchenko, et al.
Anticancer Research|September 29, 2023
From Mendel to Gene TherapySamantha L Jeffrey, Don A Brigham, Sant P Chawla, et al.
Anticancer Research|May 29, 2023
Early-stage <i>CCNG1</i>+ HR+ HER2+ Invasive Breast Carcinoma in Older Women: Current Treatment and Future Perspectives for DeltaRex-G, a <i>CCNG1</i> InhibitorSant P Chawla, Olga Olevsky, Geeta Iyengar, et al.
Frontiers in Molecular Medicine|August 1, 2024
Three year results of Blessed: Expanded access for DeltaRex-G for an intermediate size population with advanced pancreatic cancer and sarcoma (NCT04091295) and individual patient use of DeltaRex-G for solid malignancies (IND# 19130)Sant P Chawla, Steven Wong, Doris Quon, et al.
Frontiers in Oncology|May 26, 2023
Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)Sant P Chawla, Walter Andree Tellez, Hripsime Chomoyan, et al.
Pageof 1